ArticleInflammation and regeneration2026
Alveolar type II cell therapy ameliorates pulmonary fibrosis by reprogramming macrophage activation.
Article in Inflammation and regeneration, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAlveolar type II (ATII) cell transplantation is a promising therapeutic strategy for idiopathic pulmonary fibrosis, although its underlying cellular mechanisms remain incompletely understood. Given that macrophage profibrotic activation is a key driver of fibrosis, we hypothesized that ATII cell therapy exerts antifibrotic effects by reprogramming macrophage activation states during the established fibrotic phase.
methodsIn a rat model of bleomycin-induced pulmonary fibrosis, we characterized alveolar and interstitial macrophage profiles in control animals, in fibrotic animals, and after intratracheal transplantation of ATII cells performed on day 15 after bleomycin once fibrosis was established. Gene expression analyses were used to define macrophage activation profiles, while in vitro co-cultures of macrophages with ATII cells or fibroblasts assessed paracrine interactions and macrophage activation-state modulation. The CXCL12/CXCR4 signalling axis was further examined to explore potential mechanisms linking macrophage reprogramming to CXCR4⁺ cell dynamics, including recruitment of circulating CXCR4⁺ cells.
resultsDisease progression promoted a prominent profibrotic activation profile enriched in M2-associated markers in both alveolar and interstitial macrophages. ATII cell transplantation markedly reduced macrophage infiltration and shifted their activation toward a less profibrotic, more homeostatic profile. In vitro, soluble mediators released by healthy ATII cells contributed to modulation of macrophage activation states, restoring a less profibrotic activation profile. Reciprocal crosstalk between macrophages and fibroblasts was observed: fibrotic macrophages enhanced fibroblast activation, whereas macrophages from control lungs exerted antifibrotic effects. Notably, ATII cell transplantation normalised CXCL12/CXCR4 axis expression and reduced the number of circulating CXCR4⁺ cells, suggesting that modulation of this axis may limit the recruitment of circulating CXCR4⁺ cells and attenuate profibrotic signalling.
conclusionsATII cell transplantation ameliorates pulmonary fibrosis by restoring a less profibrotic immune microenvironment and modulating macrophage-fibroblast crosstalk. These effects are associated with reduced fibroblast activation and decreased accumulation of circulating CXCR4⁺ cells, consistent with attenuation of fibrotic responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.